Article Cited by others


Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation

Nurwidya Fariz, Takahashi Fumiyuki, Takahashi Kazuhisa

Year : 2016| Volume: 7| Issue : 2 | Page no: 119-123

   This article has been cited by
1 CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients
Danay Saavedra,Tania Crombet
Frontiers in Immunology. 2017; 8
[Pubmed]  [Google Scholar] [DOI]
2 Enantioselective Synthesis of Quinazoline-Based Heterocycles through Phosphine-Catalyzed Asymmetric [3+3] Annulation of Morita-Baylis-Hillman Carbonates with Azomethine Imines
Leijie Zhou,Chunhao Yuan,Cheng Zhang,Lei Zhang,Zhenzhen Gao,Chang Wang,Honglei Liu,Yang Wu,Hongchao Guo
Advanced Synthesis & Catalysis. 2017;
[Pubmed]  [Google Scholar] [DOI]
3 Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers
Rifeng Jiang,Ximin Dong,Wenzhen Zhu,Qing Duan,Yunjing Xue,Yanxia Shen,Guopeng Zhang,Chin-Tu Chen
PLOS ONE. 2017; 12(9): e0184338
[Pubmed]  [Google Scholar] [DOI]
4 Gefitinib: an “orphan” drug for non-small cell lung cancer
Dimitrios C. Ziogas,Michalis Liontos,Anastasios Kyriazoglou,Georgios Tsironis,Aristotelis Bamias,Meletios-Athanasios Dimopoulos
Expert Opinion on Orphan Drugs. 2017; 5(11): 899
[Pubmed]  [Google Scholar] [DOI]


Read this article